Drugs that contain Naloxegol Oxalate
1. Movantik patents expiration
MOVANTIK's oppositions filed in EPO
MOVANTIK Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7662365 | VALINOR | Polymer conjugates of opioid antagonists |
Oct, 2022
(1 year, 6 months ago) | |
| US7786133 | VALINOR | Chemically modified small molecules |
Sep, 2028
(4 years from now) | |
| US9012469 | VALINOR | Crystalline naloxol-peg conjugate |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617530 | VALINOR | Polymer conjugates of opioid antagonists |
Oct, 2022
(1 year, 6 months ago) | |
| US7056500 | VALINOR | Polymer conjugates of opioid antagonists |
Jun, 2024
(2 months from now) | |
| US8067431 | VALINOR | Chemically modified small molecules |
Dec, 2024
(7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 16, 2019 |
NCE-1 date: 16 September, 2018
Market Authorisation Date: 16 September, 2014
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
How can I launch a generic of MOVANTIK before it's drug patent expiration?
More Information on Dosage
MOVANTIK family patents
